Cargando…

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Bosch, Neus, Vilariño, Noelia, Alameda, Francesc, Mojal, Sergi, Arumí-Uria, Montserrat, Carrato, Cristina, Aldecoa, Iban, Ribalta, Teresa, Vidal, Noemí, Bellosillo, Beatriz, Menéndez, Silvia, Del Barco, Sonia, Gallego, Oscar, Pineda, Estela, López-Martos, Raquel, Hernández, Ainhoa, Mesia, Carlos, Esteve-Codina, Anna, de la Iglesia, Nuria, Balañá, Carme, Martínez-García, María, Navarro, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047329/
https://www.ncbi.nlm.nih.gov/pubmed/36980184
http://dx.doi.org/10.3390/cells12060843
_version_ 1785013893848891392
author Martínez-Bosch, Neus
Vilariño, Noelia
Alameda, Francesc
Mojal, Sergi
Arumí-Uria, Montserrat
Carrato, Cristina
Aldecoa, Iban
Ribalta, Teresa
Vidal, Noemí
Bellosillo, Beatriz
Menéndez, Silvia
Del Barco, Sonia
Gallego, Oscar
Pineda, Estela
López-Martos, Raquel
Hernández, Ainhoa
Mesia, Carlos
Esteve-Codina, Anna
de la Iglesia, Nuria
Balañá, Carme
Martínez-García, María
Navarro, Pilar
author_facet Martínez-Bosch, Neus
Vilariño, Noelia
Alameda, Francesc
Mojal, Sergi
Arumí-Uria, Montserrat
Carrato, Cristina
Aldecoa, Iban
Ribalta, Teresa
Vidal, Noemí
Bellosillo, Beatriz
Menéndez, Silvia
Del Barco, Sonia
Gallego, Oscar
Pineda, Estela
López-Martos, Raquel
Hernández, Ainhoa
Mesia, Carlos
Esteve-Codina, Anna
de la Iglesia, Nuria
Balañá, Carme
Martínez-García, María
Navarro, Pilar
author_sort Martínez-Bosch, Neus
collection PubMed
description Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.
format Online
Article
Text
id pubmed-10047329
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100473292023-03-29 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker Martínez-Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí-Uria, Montserrat Carrato, Cristina Aldecoa, Iban Ribalta, Teresa Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Del Barco, Sonia Gallego, Oscar Pineda, Estela López-Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve-Codina, Anna de la Iglesia, Nuria Balañá, Carme Martínez-García, María Navarro, Pilar Cells Article Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM. MDPI 2023-03-08 /pmc/articles/PMC10047329/ /pubmed/36980184 http://dx.doi.org/10.3390/cells12060843 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martínez-Bosch, Neus
Vilariño, Noelia
Alameda, Francesc
Mojal, Sergi
Arumí-Uria, Montserrat
Carrato, Cristina
Aldecoa, Iban
Ribalta, Teresa
Vidal, Noemí
Bellosillo, Beatriz
Menéndez, Silvia
Del Barco, Sonia
Gallego, Oscar
Pineda, Estela
López-Martos, Raquel
Hernández, Ainhoa
Mesia, Carlos
Esteve-Codina, Anna
de la Iglesia, Nuria
Balañá, Carme
Martínez-García, María
Navarro, Pilar
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title_full Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title_fullStr Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title_full_unstemmed Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title_short Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
title_sort gal-1 expression analysis in the gliocat multicenter study: role as a prognostic factor and an immune-suppressive biomarker
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047329/
https://www.ncbi.nlm.nih.gov/pubmed/36980184
http://dx.doi.org/10.3390/cells12060843
work_keys_str_mv AT martinezboschneus gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT vilarinonoelia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT alamedafrancesc gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT mojalsergi gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT arumiuriamontserrat gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT carratocristina gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT aldecoaiban gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT ribaltateresa gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT vidalnoemi gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT bellosillobeatriz gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT menendezsilvia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT delbarcosonia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT gallegooscar gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT pinedaestela gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT lopezmartosraquel gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT hernandezainhoa gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT mesiacarlos gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT estevecodinaanna gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT delaiglesianuria gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT balanacarme gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT martinezgarciamaria gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker
AT navarropilar gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker